One-year changes in brain microstructure differentiate preclinical Huntington's disease stages

Chris Patrick Pflanz, Marina Charquero-Ballester, D. S.Adnan Majid, Anderson M. Winkler, Emmanuel Vallée, Adam R. Aron, Mark Jenkinson, Gwenaëlle Douaud

Research output: Contribution to journalArticle

Abstract

Objective: To determine whether brain imaging markers of tissue microstructure can detect the effect of disease progression across the preclinical stages of Huntington's disease. Methods: Longitudinal microstructural changes in diffusion imaging metrics (mean diffusivity and fractional anisotropy) were investigated in participants with presymptomatic Huntington's disease (N = 35) stratified into three preclinical subgroups according to their estimated time until onset of symptoms, compared with age- and gender-matched healthy controls (N = 19) over a 1y period. Results: Significant differences were found over the four groups in change of mean diffusivity in the posterior basal ganglia and the splenium of the corpus callosum. This overall effect was driven by significant differences between the group far-from-onset (FAR) of symptoms and the groups midway- (MID) and near-the-onset (NEAR) of symptoms. In particular, an initial decrease of mean diffusivity in the FAR group was followed by a subsequent increase in groups closer to onset of symptoms. The seemingly counter-intuitive decrease of mean diffusivity in the group furthest from onset of symptoms might be an early indicator of neuroinflammatory process preceding the neurodegenerative phase. In contrast, the only clinical measure that was able to capture a difference in 1y changes between the preclinical stages was the UHDRS confidence in motor score. Conclusions: With sensitivity to longitudinal changes in brain microstructure within and between preclinical stages, and potential differential response to distinct pathophysiological mechanisms, diffusion imaging is a promising state marker for monitoring treatment response and identifying the optimal therapeutic window of opportunity in preclinical Huntington's disease.

LanguageEnglish
Article number102099
JournalNeuroImage: Clinical
Volume25
DOIs
Publication statusPublished - 1 Jan 2020
Externally publishedYes

Keywords

  • Basal ganglia
  • Corpus callosum
  • Diffusion imaging
  • Longitudinal
  • Microstructure
  • Preclinical Huntington's disease

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Pflanz, C. P., Charquero-Ballester, M., Majid, D. S. A., Winkler, A. M., Vallée, E., Aron, A. R., ... Douaud, G. (2020). One-year changes in brain microstructure differentiate preclinical Huntington's disease stages. NeuroImage: Clinical, 25, [102099]. https://doi.org/10.1016/j.nicl.2019.102099
Pflanz, Chris Patrick ; Charquero-Ballester, Marina ; Majid, D. S.Adnan ; Winkler, Anderson M. ; Vallée, Emmanuel ; Aron, Adam R. ; Jenkinson, Mark ; Douaud, Gwenaëlle. / One-year changes in brain microstructure differentiate preclinical Huntington's disease stages. In: NeuroImage: Clinical. 2020 ; Vol. 25.
@article{5aab90ffe5ec4311995e616897d0dbaf,
title = "One-year changes in brain microstructure differentiate preclinical Huntington's disease stages",
abstract = "Objective: To determine whether brain imaging markers of tissue microstructure can detect the effect of disease progression across the preclinical stages of Huntington's disease. Methods: Longitudinal microstructural changes in diffusion imaging metrics (mean diffusivity and fractional anisotropy) were investigated in participants with presymptomatic Huntington's disease (N = 35) stratified into three preclinical subgroups according to their estimated time until onset of symptoms, compared with age- and gender-matched healthy controls (N = 19) over a 1y period. Results: Significant differences were found over the four groups in change of mean diffusivity in the posterior basal ganglia and the splenium of the corpus callosum. This overall effect was driven by significant differences between the group far-from-onset (FAR) of symptoms and the groups midway- (MID) and near-the-onset (NEAR) of symptoms. In particular, an initial decrease of mean diffusivity in the FAR group was followed by a subsequent increase in groups closer to onset of symptoms. The seemingly counter-intuitive decrease of mean diffusivity in the group furthest from onset of symptoms might be an early indicator of neuroinflammatory process preceding the neurodegenerative phase. In contrast, the only clinical measure that was able to capture a difference in 1y changes between the preclinical stages was the UHDRS confidence in motor score. Conclusions: With sensitivity to longitudinal changes in brain microstructure within and between preclinical stages, and potential differential response to distinct pathophysiological mechanisms, diffusion imaging is a promising state marker for monitoring treatment response and identifying the optimal therapeutic window of opportunity in preclinical Huntington's disease.",
keywords = "Basal ganglia, Corpus callosum, Diffusion imaging, Longitudinal, Microstructure, Preclinical Huntington's disease",
author = "Pflanz, {Chris Patrick} and Marina Charquero-Ballester and Majid, {D. S.Adnan} and Winkler, {Anderson M.} and Emmanuel Vall{\'e}e and Aron, {Adam R.} and Mark Jenkinson and Gwena{\"e}lle Douaud",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.nicl.2019.102099",
language = "English",
volume = "25",
journal = "NeuroImage: Clinical",
issn = "2213-1582",

}

Pflanz, CP, Charquero-Ballester, M, Majid, DSA, Winkler, AM, Vallée, E, Aron, AR, Jenkinson, M & Douaud, G 2020, 'One-year changes in brain microstructure differentiate preclinical Huntington's disease stages', NeuroImage: Clinical, vol. 25, 102099. https://doi.org/10.1016/j.nicl.2019.102099

One-year changes in brain microstructure differentiate preclinical Huntington's disease stages. / Pflanz, Chris Patrick; Charquero-Ballester, Marina; Majid, D. S.Adnan; Winkler, Anderson M.; Vallée, Emmanuel; Aron, Adam R.; Jenkinson, Mark; Douaud, Gwenaëlle.

In: NeuroImage: Clinical, Vol. 25, 102099, 01.01.2020.

Research output: Contribution to journalArticle

TY - JOUR

T1 - One-year changes in brain microstructure differentiate preclinical Huntington's disease stages

AU - Pflanz, Chris Patrick

AU - Charquero-Ballester, Marina

AU - Majid, D. S.Adnan

AU - Winkler, Anderson M.

AU - Vallée, Emmanuel

AU - Aron, Adam R.

AU - Jenkinson, Mark

AU - Douaud, Gwenaëlle

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Objective: To determine whether brain imaging markers of tissue microstructure can detect the effect of disease progression across the preclinical stages of Huntington's disease. Methods: Longitudinal microstructural changes in diffusion imaging metrics (mean diffusivity and fractional anisotropy) were investigated in participants with presymptomatic Huntington's disease (N = 35) stratified into three preclinical subgroups according to their estimated time until onset of symptoms, compared with age- and gender-matched healthy controls (N = 19) over a 1y period. Results: Significant differences were found over the four groups in change of mean diffusivity in the posterior basal ganglia and the splenium of the corpus callosum. This overall effect was driven by significant differences between the group far-from-onset (FAR) of symptoms and the groups midway- (MID) and near-the-onset (NEAR) of symptoms. In particular, an initial decrease of mean diffusivity in the FAR group was followed by a subsequent increase in groups closer to onset of symptoms. The seemingly counter-intuitive decrease of mean diffusivity in the group furthest from onset of symptoms might be an early indicator of neuroinflammatory process preceding the neurodegenerative phase. In contrast, the only clinical measure that was able to capture a difference in 1y changes between the preclinical stages was the UHDRS confidence in motor score. Conclusions: With sensitivity to longitudinal changes in brain microstructure within and between preclinical stages, and potential differential response to distinct pathophysiological mechanisms, diffusion imaging is a promising state marker for monitoring treatment response and identifying the optimal therapeutic window of opportunity in preclinical Huntington's disease.

AB - Objective: To determine whether brain imaging markers of tissue microstructure can detect the effect of disease progression across the preclinical stages of Huntington's disease. Methods: Longitudinal microstructural changes in diffusion imaging metrics (mean diffusivity and fractional anisotropy) were investigated in participants with presymptomatic Huntington's disease (N = 35) stratified into three preclinical subgroups according to their estimated time until onset of symptoms, compared with age- and gender-matched healthy controls (N = 19) over a 1y period. Results: Significant differences were found over the four groups in change of mean diffusivity in the posterior basal ganglia and the splenium of the corpus callosum. This overall effect was driven by significant differences between the group far-from-onset (FAR) of symptoms and the groups midway- (MID) and near-the-onset (NEAR) of symptoms. In particular, an initial decrease of mean diffusivity in the FAR group was followed by a subsequent increase in groups closer to onset of symptoms. The seemingly counter-intuitive decrease of mean diffusivity in the group furthest from onset of symptoms might be an early indicator of neuroinflammatory process preceding the neurodegenerative phase. In contrast, the only clinical measure that was able to capture a difference in 1y changes between the preclinical stages was the UHDRS confidence in motor score. Conclusions: With sensitivity to longitudinal changes in brain microstructure within and between preclinical stages, and potential differential response to distinct pathophysiological mechanisms, diffusion imaging is a promising state marker for monitoring treatment response and identifying the optimal therapeutic window of opportunity in preclinical Huntington's disease.

KW - Basal ganglia

KW - Corpus callosum

KW - Diffusion imaging

KW - Longitudinal

KW - Microstructure

KW - Preclinical Huntington's disease

UR - http://www.scopus.com/inward/record.url?scp=85076684823&partnerID=8YFLogxK

U2 - 10.1016/j.nicl.2019.102099

DO - 10.1016/j.nicl.2019.102099

M3 - Article

VL - 25

JO - NeuroImage: Clinical

T2 - NeuroImage: Clinical

JF - NeuroImage: Clinical

SN - 2213-1582

M1 - 102099

ER -

Pflanz CP, Charquero-Ballester M, Majid DSA, Winkler AM, Vallée E, Aron AR et al. One-year changes in brain microstructure differentiate preclinical Huntington's disease stages. NeuroImage: Clinical. 2020 Jan 1;25. 102099. https://doi.org/10.1016/j.nicl.2019.102099